Biocare Medical, a San Francisco, CA-based supplier of immunohistochemistry (IHC) and FISH, acquired Empire Genomics, a Buffalo, NY-based supplier of molecular biomarkers.
The quantity of the deal was undisclosed.
Collectively, Biocare Medical and Empire Genomics will deliver an expanded providing of options to these researching and diagnosing most cancers around the globe.
Empire Genomics is a supplier of FISH and ISH, providing over a million biomarkers. These biomarkers allow analysis and scientific establishments to deliver clinically related assessments. The corporate allows analysis to rework into impactful scientific and analysis instruments worldwide. The great product portfolio consists of Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization (CISH) probes designed and optimized for particular illnesses, genes, or areas throughout the whole human and mouse genomes.
Led by CEO Luis de Luzuriaga, Biocare Medical is a supplier of options for most cancers analysis and diagnostics, offering: reagents, together with tissue-conserving simultaneous Multiplex IHC antibody cocktails and detections; Buyer Care; and a complete suite of instrumentation for IHC, molecular, and histology testing. Its reagent portfolio consists of major antibodies, Multiplex IHC, and FISH probes for goal indications. Biocare additionally provides a line of polymer detections for scientific, human, and animal analysis that ship excessive sensitivity and exceptionally low background. The corporate’s automated instrument platforms, intelliPATH and ONCORE Professional, have been designed to satisfy each want from excessive throughput scientific diagnostics to versatile analysis necessities.
Clients embrace scientific anatomic pathology laboratories, pharmaceutical firms, CROs, and biotechnology firms in addition to educational, authorities, navy, and different non-profit laboratories